Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics - PubMed (original) (raw)
. 2012 Mar;135(Pt 3):794-806.
doi: 10.1093/brain/aws001.
Stephen D Weigand, Bradley F Boeve, Matthew L Senjem, Jeffrey L Gunter, Mariely DeJesus-Hernandez, Nicola J Rutherford, Matthew Baker, David S Knopman, Zbigniew K Wszolek, Joseph E Parisi, Dennis W Dickson, Ronald C Petersen, Rosa Rademakers, Clifford R Jack Jr, Keith A Josephs
Affiliations
- PMID: 22366795
- PMCID: PMC3286334
- DOI: 10.1093/brain/aws001
Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics
Jennifer L Whitwell et al. Brain. 2012 Mar.
Abstract
A major recent discovery was the identification of an expansion of a non-coding GGGGCC hexanucleotide repeat in the C9ORF72 gene in patients with frontotemporal dementia and amyotrophic lateral sclerosis. Mutations in two other genes are known to account for familial frontotemporal dementia: microtubule-associated protein tau and progranulin. Although imaging features have been previously reported in subjects with mutations in tau and progranulin, no imaging features have been published in C9ORF72. Furthermore, it remains unknown whether there are differences in atrophy patterns across these mutations, and whether regional differences could help differentiate C9ORF72 from the other two mutations at the single-subject level. We aimed to determine the regional pattern of brain atrophy associated with the C9ORF72 gene mutation, and to determine which regions best differentiate C9ORF72 from subjects with mutations in tau and progranulin, and from sporadic frontotemporal dementia. A total of 76 subjects, including 56 with a clinical diagnosis of behavioural variant frontotemporal dementia and a mutation in one of these genes (19 with C9ORF72 mutations, 25 with tau mutations and 12 with progranulin mutations) and 20 sporadic subjects with behavioural variant frontotemporal dementia (including 50% with amyotrophic lateral sclerosis), with magnetic resonance imaging were included in this study. Voxel-based morphometry was used to assess and compare patterns of grey matter atrophy. Atlas-based parcellation was performed utilizing the automated anatomical labelling atlas and Statistical Parametric Mapping software to compute volumes of 37 regions of interest. Hemispheric asymmetry was calculated. Penalized multinomial logistic regression was utilized to create a prediction model to discriminate among groups using regional volumes and asymmetry score. Principal component analysis assessed for variance within groups. C9ORF72 was associated with symmetric atrophy predominantly involving dorsolateral, medial and orbitofrontal lobes, with additional loss in anterior temporal lobes, parietal lobes, occipital lobes and cerebellum. In contrast, striking anteromedial temporal atrophy was associated with tau mutations and temporoparietal atrophy was associated with progranulin mutations. The sporadic group was associated with frontal and anterior temporal atrophy. A conservative penalized multinomial logistic regression model identified 14 variables that could accurately classify subjects, including frontal, temporal, parietal, occipital and cerebellum volume. The principal component analysis revealed similar degrees of heterogeneity within all disease groups. Patterns of atrophy therefore differed across subjects with C9ORF72, tau and progranulin mutations and sporadic frontotemporal dementia. Our analysis suggested that imaging has the potential to be useful to help differentiate C9ORF72 from these other groups at the single-subject level.
Figures
Figure 1
Results of the voxel-based morphometry analysis of grey matter volume. (A) Patterns of grey matter loss in MAPT, GRN, C9ORF72 and sporadic FTD groups compared with controls, at P < 0.05 (corrected for multiple comparisons using family-wise error). (B) Differences in grey matter volume between the C9ORF72 group and the other disease groups, at P < 0.001 (uncorrected for multiple comparisons). Results are shown in 3D renderings of the brain.
Figure 2
Box plots of all variables selected in the penalized multinomial logistic regression model as best for differentiating disease groups. All regional grey matter volumes were divided by whole brain volume to correct for differences in global atrophy between subjects. This step was performed because we were interested in assessing the relative involvement of each region, without confounds of global severity. L = left; R = right; ROI = region of interest.
Figure 3
Box plots of variables that were not selected in the penalized multinomial logistic regression model as useful for differentiating disease groups, and hence not shown in Fig. 2. All regional grey matter volumes were divided by whole brain volume to correct for differences in global atrophy between subjects. This step was performed because we were interested in assessing the relative involvement of each region, without confounds of global severity. L = left; R = right; ROI = region of interest.
Figure 4
Coefficients for the 14 variables that were retained in the final penalized multinomial logistic regression for the MAPT, GRN, C9ORF72 and sporadic FTD groups. A negative coefficient means that lower values (i.e. more atrophy) on that variable increases the estimated probability of being in that group, holding all other variables constant. L = left; R = right.
Figure 5
Plots showing the estimated probability of MAPT, GRN, C9ORF72 and sporadic FTD according to volume for each of the 14 variables that were retained in the final model. In each panel, the adjustment covariates are set to their mean values. L = left; R = right; ROI = region of interest.
Figure 6
Plot of the cumulative proportion of variability explained by each principal component for the C9ORF72, MAPT, GRN and sporadic FTD groups.
Comment in
- The C9ORF72 syndrome: implications for clinical practice.
Robertson NP. Robertson NP. J Neurol. 2012 Apr;259(4):794-6. doi: 10.1007/s00415-012-6479-5. J Neurol. 2012. PMID: 22430253 No abstract available.
Similar articles
- The clinical and pathological phenotype of C9ORF72 hexanucleotide repeat expansions.
Simón-Sánchez J, Dopper EG, Cohn-Hokke PE, Hukema RK, Nicolaou N, Seelaar H, de Graaf JR, de Koning I, van Schoor NM, Deeg DJ, Smits M, Raaphorst J, van den Berg LH, Schelhaas HJ, De Die-Smulders CE, Majoor-Krakauer D, Rozemuller AJ, Willemsen R, Pijnenburg YA, Heutink P, van Swieten JC. Simón-Sánchez J, et al. Brain. 2012 Mar;135(Pt 3):723-35. doi: 10.1093/brain/awr353. Epub 2012 Feb 1. Brain. 2012. PMID: 22300876 - Brain atrophy over time in genetic and sporadic frontotemporal dementia: a study of 198 serial magnetic resonance images.
Whitwell JL, Boeve BF, Weigand SD, Senjem ML, Gunter JL, Baker MC, DeJesus-Hernandez M, Knopman DS, Wszolek ZK, Petersen RC, Rademakers R, Jack CR Jr, Josephs KA. Whitwell JL, et al. Eur J Neurol. 2015 May;22(5):745-52. doi: 10.1111/ene.12675. Epub 2015 Feb 12. Eur J Neurol. 2015. PMID: 25683866 Free PMC article. - Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72.
Boeve BF, Boylan KB, Graff-Radford NR, DeJesus-Hernandez M, Knopman DS, Pedraza O, Vemuri P, Jones D, Lowe V, Murray ME, Dickson DW, Josephs KA, Rush BK, Machulda MM, Fields JA, Ferman TJ, Baker M, Rutherford NJ, Adamson J, Wszolek ZK, Adeli A, Savica R, Boot B, Kuntz KM, Gavrilova R, Reeves A, Whitwell J, Kantarci K, Jack CR Jr, Parisi JE, Lucas JA, Petersen RC, Rademakers R. Boeve BF, et al. Brain. 2012 Mar;135(Pt 3):765-83. doi: 10.1093/brain/aws004. Brain. 2012. PMID: 22366793 Free PMC article. - Phenotypic signatures of genetic frontotemporal dementia.
Rohrer JD, Warren JD. Rohrer JD, et al. Curr Opin Neurol. 2011 Dec;24(6):542-9. doi: 10.1097/WCO.0b013e32834cd442. Curr Opin Neurol. 2011. PMID: 21986680 Review. - Frontotemporal dementia.
Deleon J, Miller BL. Deleon J, et al. Handb Clin Neurol. 2018;148:409-430. doi: 10.1016/B978-0-444-64076-5.00027-2. Handb Clin Neurol. 2018. PMID: 29478591 Review.
Cited by
- A Case of Personality and Behavioral Changes with Frontotemporal and Cerebellar Atrophy on MRI with Corresponding Hypometabolism on FDG-PET.
Selig M, Lee G, Lebowitz B, Franceschi D, Absar N. Selig M, et al. Case Rep Psychiatry. 2024 Aug 19;2024:2863662. doi: 10.1155/2024/2863662. eCollection 2024. Case Rep Psychiatry. 2024. PMID: 39188506 Free PMC article. - Basal parasympathetic deficits in C9orf72 hexanucleotide repeat expansion carriers relate to smaller frontoinsula and thalamus volume and lower empathy.
R K Roy A, Noohi F, Morris NA, Ljubenkov P, Heuer H, Fong J, Hall M, Lario Lago A, Rankin KP, Miller BL, Boxer AL, Rosen HJ, Seeley WW, Perry DC, Yokoyama JS, Lee SE, Sturm VE. R K Roy A, et al. Neuroimage Clin. 2024;43:103649. doi: 10.1016/j.nicl.2024.103649. Epub 2024 Jul 29. Neuroimage Clin. 2024. PMID: 39098187 Free PMC article. - Limbic Network and Papez Circuit Involvement in ALS: Imaging and Clinical Profiles in GGGGCC Hexanucleotide Carriers in C9orf72 and _C9orf72_-Negative Patients.
Christidi F, Kleinerova J, Tan EL, Delaney S, Tacheva A, Hengeveld JC, Doherty MA, McLaughlin RL, Hardiman O, Siah WF, Chang KM, Lope J, Bede P. Christidi F, et al. Biology (Basel). 2024 Jul 6;13(7):504. doi: 10.3390/biology13070504. Biology (Basel). 2024. PMID: 39056697 Free PMC article. - Longitudinal cerebral perfusion in presymptomatic genetic frontotemporal dementia: GENFI results.
Pasternak M, Mirza SS, Luciw N, Mutsaerts HJMM, Petr J, Thomas D, Cash D, Bocchetta M, Tartaglia MC, Mitchell SB, Black SE, Freedman M, Tang-Wai D, Rogaeva E, Russell LL, Bouzigues A, van Swieten JC, Jiskoot LC, Seelaar H, Laforce R Jr, Tiraboschi P, Borroni B, Galimberti D, Rowe JB, Graff C, Finger E, Sorbi S, de Mendonça A, Butler C, Gerhard A, Sanchez-Valle R, Moreno F, Synofzik M, Vandenberghe R, Ducharme S, Levin J, Otto M, Santana I, Strafella AP, MacIntosh BJ, Rohrer JD, Masellis M; GENetic Frontotemporal dementia Initiative (GENFI). Pasternak M, et al. Alzheimers Dement. 2024 May;20(5):3525-3542. doi: 10.1002/alz.13750. Epub 2024 Apr 16. Alzheimers Dement. 2024. PMID: 38623902 Free PMC article. Italian. - Primary Progressive Apraxia of Speech Caused by TDP-43: A Case Report.
Meade G, Whitwell JL, Dickson DW, Duffy JR, Clark HM, Ahlskog JE, Machulda MM, Josephs KA, Utianski RL. Meade G, et al. Neurol Genet. 2024 Mar 19;10(2):e200134. doi: 10.1212/NXG.0000000000200134. eCollection 2024 Apr. Neurol Genet. 2024. PMID: 38515991 Free PMC article.
References
- Agresti A. New York: Wiley-Interscience; 2002. Categorical data analysis.
- Al-Sarraj S, King A, Troakes C, Smith B, Maekawa S, Bodi I, et al. p62 positive, TDP-43 negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9orf72-linked FTLD and MND/ALS. Acta Neuropathol. 2011;122:691–702. - PubMed
- Arvanitakis Z, Witte RJ, Dickson DW, Tsuboi Y, Uitti RJ, Slowinski J, et al. Clinical-pathologic study of biomarkers in FTDP-17 (PPND family with N279K tau mutation) Parkinsonism Relat Disord. 2007;13:230–9. - PubMed
- Ashburner J, Friston KJ. Voxel-based morphometry–the methods. Neuroimage. 2000;11:805–21. - PubMed
- Ashburner J, Friston KJ. Unified segmentation. Neuroimage. 2005;26:839–51. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- P50 AG16574/AG/NIA NIH HHS/United States
- R01 AG11378/AG/NIA NIH HHS/United States
- P50 AG016574/AG/NIA NIH HHS/United States
- NS057567/NS/NINDS NIH HHS/United States
- U01 AG03949/AG/NIA NIH HHS/United States
- U01 AG024904/AG/NIA NIH HHS/United States
- P50-AG25711/AG/NIA NIH HHS/United States
- P50 NS072187-01S2/NS/NINDS NIH HHS/United States
- U01 AG06786/AG/NIA NIH HHS/United States
- R01 DC010367/DC/NIDCD NIH HHS/United States
- U24 AG026395/AG/NIA NIH HHS/United States
- R56 AG26251-03/AG/NIA NIH HHS/United States
- 1RC2NS070276/NS/NINDS NIH HHS/United States
- R01 HL70825/HL/NHLBI NIH HHS/United States
- R01-AG023195/AG/NIA NIH HHS/United States
- P01-AG17216/AG/NIA NIH HHS/United States
- R21 AG38736/AG/NIA NIH HHS/United States
- R01 AG011378/AG/NIA NIH HHS/United States
- R01-AG26251/AG/NIA NIH HHS/United States
- P50-NS40256/NS/NINDS NIH HHS/United States
- R01 NS065782/NS/NINDS NIH HHS/United States
- R01-NS65782/NS/NINDS NIH HHS/United States
- R01 NS065782-01/NS/NINDS NIH HHS/United States
- R01 AG037491/AG/NIA NIH HHS/United States
- P01 AG003949/AG/NIA NIH HHS/United States
- R01-AG15866/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous